Experts doubtful of Idorsia’s daridorexant uptake potential in insomnia
Idorsia’s daridorexant has experts unsure of its uptake potential due to a lack of differentiation from an already approved insomnia therapy...
Trending menu:
-
![Biogen’s aducanumab leans toward conditional versus full approval in Alzheimer’s]()
Biogen’s aducanumab leans toward conditional versus full approval in Alzheimer’s
-
![Experts sceptical on Bristol-Myers Squibb’s head and neck cancer trial of Opdivo]()
Experts sceptical on Bristol-Myers Squibb’s head and neck cancer trial of Opdivo
-
![UniQure’s etranacogene dezaparvovec in haemophilia B has experts positive on Phase III prospects]()
UniQure’s etranacogene dezaparvovec in haemophilia B has experts positive on Phase III prospects
-
![Overview of industry-sponsored clinical trials in the UK, 2019]()
Overview of industry-sponsored clinical trials in the UK, 2019
-
![UCB’s bimekizumab outperforms AbbVie’s Humira in psoriasis patients]()
UCB’s bimekizumab outperforms AbbVie’s Humira in psoriasis patients
-
![Benchmarking Phase II industry-sponsored colorectal cancer trials]()
Benchmarking Phase II industry-sponsored colorectal cancer trials
Expert commentary & analysis from GlobalData
Gene silencing therapy’s fast-track approval to expand treatment options for Huntington’s patients
iRhythm to participate in atrial fibrillation study to reduce stroke rates
BeiGene’s Phase III Trial of Zanubrutinib Misses Late-Stage Goals in Waldenström’s Macroglobulinemia
Report raises doubts about influential clinical trial and heart disease guidelines
Most Read
Company releases
2020 Forthcoming Events
Below are the forthcoming shows that will exhibit Malvern’s pharmaceutical solutions.
Emisphere Development Update
3DforScience Showed its Visual Solutions at ESMO Congress Barcelona
The European Society for Medical Oncology (ESMO) Congress took place Barcelona from 27 September to 1 October 2019. This was...
Hybrid Solutions
Enterprise API and Mobile Applications
We created our Enterprise API to deliver your data to you in a secure manner...
Company whitepapers
AtreMorine: A Biotechnological / Nutraceutical product for Parkinson’s
EuroEspes BiotechnologyStudy: Pharmacokinetics of Oral Cyanocobalamin Formulated with SNAC
Emisphere TechnologiesIoT Tracking and Monitoring
OnAsset IntelligenceUnderstanding Sucrose: Matching Sucrose Quality to Functional Need
PfanstiehlTrehalose: A Powerful Excipient in the Formulation Toolbox
PfanstiehlSupporting the Pharmaceutical Industry, 21 CFR Part 11 Compliance Readiness
Malvern PanalyticalIKA Laboratory Equipment Brochure
Ika-WerkeCompany A-Z
Clinical Trials
Innovation Pharmaceuticals doses first cohort in oral brilacidin trial
Innovation Pharmaceuticals has completed dosing of the first cohort of subjects in its Phase I trial of oral brilacidin.
Neuroptika enrols first patient for dry eye disease trial
BioTheryX initiates patient dosing in trial of BTX-A51 for AML
BerGenBio reports positive results from first stage of NSCLC study
Euan MacDonald Centre launches motor neurone disease trials in UK
Drug Development
Verona Pharma reports positive top-line data from COPD trial
Verona Pharma has reported positive top-line data from a Phase IIb dose-ranging study assessing the efficacy of ensifentrine for the treatment of chronic obstructive pulmonary...
Terns Pharmaceuticals reports positive results from TERN-201 trial
Zymeworks begins trial to test ZW25 as a combination therapy
ADC Therapeutics reports positive results from loncastuximab tesirine trial
Regeneron reports positive data from rare bone disease trials
Your recommended content
Supporting mental health in a business environment
Download a free 10 page preview of our Mergers & Acquisitions in TMT – Thematic Research 2019 Report
Go Top